• Sign In
  • Home
  • News
    • Politics
      • White House
      • Senate
      • House
      • Campaigns
  • Policy
  • 2026 Election
  • Opinion
    • Editorials
    • Op-Eds
  • In Focus
  • Restoring America
  • Magazine
  • Watch
  • Sponsored
    • Powering Progress
    • ASAE – Association Leadership
    • Examining Tax Reform
    • Fix TSCA
    • National Parks
    • Inside the Corn Belt
  • TWS Archive
Search
LogoWashington Examiner
Subscribe
LogoWashington Examiner
Sign in
Subscribe
  • News
    • Politics
      • Trump Administration
      • White House
      • Senate
      • House
      • Campaigns
    • Business
    • World
    • Investigations
    • Justice
    • Supreme Court
    • Crime
    • Entertainment
    • Washington Secrets
  • Policy
    • Defense
    • National Security
    • Energy and Environment
    • Education
    • Immigration
    • Finance and Economy
    • Healthcare
    • Foreign Policy
    • Tech
    • Infrastructure
    • Space
  • 2026 Election
  • Trump Administration
  • IN FOCUS
  • Commentary
    • Columnists
    • Editorials
    • Think Tanks
    • Beltway Confidential
    • Op-Eds
  • Restoring America
    • Patriotism and Unity
    • Faith, Freedom, and Self-Reliance
    • Courage, Strength, and Optimism
    • Equality, Not Elitism
    • Community and Family
    • Fairness and Justice
    • Mission
  • Watch
  • Magazine
    • Magazine
    • Quarterly Briefing
    • Archives
    • Games
  • Sponsored
    • Powering Progress
    • ASAE – Association Leadership
    • National Parks
    • Examining Tax Reform
    • Fix TSCA
    • Inside the Corn Belt
  • Newsletters
More
    Home Tags FDA

    Tag: FDA

    Purdue argues that any statements that the painkillers shouldn't be used for noncancer pain would go against FDA labeling and conflict with its obligations under federal law. (AP Photo/Douglas Healey, File)
    Healthcare

    Opioid maker cites FDA decisions in defense against Ohio lawsuit

    Robert King -
    September 11, 2017 3:36 pm
    0
    If the FDA's vaping rule is not significantly reformed, the vast majority of independent e-cigarette businesses will be forced to shut their doors in 2022. (AP Photo/Richard Vogel)
    Beltway Confidential

    Will we ever get the truth behind the FDA’s devastating vaping rule?

    Guy Bentley -
    September 8, 2017 3:19 pm
    0
    On Wednesday, the Food and Drug Administration approved the first gene therapy in the U.S. called Kymriah, which customize a patient's own immune cells to fight a type of leukemia through a therapy called CAR-T. The drug's maker, Novartis, plans to sell the treatment for $475,000 for the one-time dose. (AP Photo/Andrew Harnik, File)
    Healthcare

    Revolutionary cancer treatment comes with hefty price tag

    Robert King -
    August 30, 2017 9:25 pm
    0
    With Obamacare reform out of the national limelight, for now, Congress should be looking for bold new ideas to make healthcare more affordable. (AP Photo/Patrick Sison)
    Beltway Confidential

    On prescription drugs, patients must be ‘free to choose’

    Casey Given -
    August 23, 2017 6:30 pm
    0
    President Trump signed into law the FDA Reauthorization Act of 2017 on Friday. It reauthorizes a program in which drug and device makers pay the FDA a fee for every new product application, and the agency uses that money to hire more people and speed up approvals. (AP Photo/Andrew Harnik, File)
    Healthcare

    Trump signs FDA funding bill

    Robert King -
    August 18, 2017 9:45 pm
    0
    Manufacturers did 38 trials for the 22 drugs approved through the FDA's expedited approval process. Of those trials, only 19 were completed within three years. (AP Photo/Gregory Bull)
    Healthcare

    Speedy drug approvals lacking in follow-up

    Robert King -
    August 16, 2017 8:39 pm
    0
    FDA Commissioner Scott Gottlieb recently unveiled a major shift in federal tobacco policy, heralding a new approach with the potential to champion public health through innovation, harm reduction and consumer choice over a one-size fits all approach manifested in outdated regulation. (AP Photo/Nam Y. Huh, File)
    Beltway Confidential

    Evidence over prejudice: Ending the anti-vaping hysteria

    Guy Bentley -
    August 11, 2017 5:31 pm
    0
    Shkreli is charged with using an investment fund to prop up the earnings for the Retrophin. (AP Photo/Susan Walsh, File)
    Crime

    Martin Shkreli leaves a legacy on Capitol Hill

    Robert King -
    August 5, 2017 12:22 am
    0
    The bill reauthorizes the FDA's program through which it charges fees for new drug or device applications. (iStock photo)
    Healthcare

    Senate passes FDA funding package

    Robert King -
    August 3, 2017 4:47 pm
    0
    The bill would allow terminally ill patients the right to try experimental treatments that have not been approved when no alternatives exist. (iStock photo)
    Healthcare

    Senate passes bill to give terminally ill patients access to experimental drugs

    Robert King -
    August 3, 2017 4:18 pm
    0
    1...131132133...182Page 132 of 182
    LogoWashington Examiner
    Do Not Sell or Share My Personal Information
    Facebook
    Twitter
    Youtube

    NEWS

    • Politics
      • White House
      • Senate
      • House
      • Campaigns
    • Business
    • World
    • Investigations
    • Justice
    • Supreme Court
    • Crime
    • Washington Secrets
    • Entertainment
    • Sports

    POLICY

    • Defense
    • National Security
    • Energy
    • Immigration
    • Finance and Economy
    • Healthcare
    • Foreign Policy
    • Tech
    • Infrastructure
    • Space

    COMMENTARY

    • Columnists
    • Editorials
    • Think Tanks
    • Beltway Confidential
    • Op-Eds

    RESTORING AMERICA

    • Patriotism and Unity
    • Faith, Freedom, and Self-Reliance
    • Courage, Strength, and Optimism
    • Equality, Not Elitism
    • Community and Family
    • Fairness and Justice
    • Mission
    • WATCH
    • IN FOCUS
    • NEWSLETTERS
    • MAGAZINE ARCHIVE
    • Policies and Standards
    • Terms Of Service
    • Subscription Terms of Use
    • Privacy Policy
    • Your Privacy Choices
    • Transparency In Coverage
    • Advertise
    • Subscribe
    • Contact
    • Careers
    • Staff
    • About Examiner
    • Facebook
    • Twitter
    • © Copyright 2026. Washington Examiner. All Rights Reserved.